BioRem Inc. Logo

BioRem Inc.

BRM.V

(1.0)
Stock Price

2,46 CAD

3.61% ROA

15% ROE

24.15x PER

Market Cap.

14.768.148,00 CAD

78.61% DER

0% Yield

2.67% NPM

BioRem Inc. Stock Analysis

BioRem Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

BioRem Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (24.61%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 ROA

The stock's ROA (5.35%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

3 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (2) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

4 PBV

The stock's elevated P/BV ratio (3.2x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

5 DER

The company has a high debt to equity ratio (118%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

10 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

11 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

BioRem Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

BioRem Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

BioRem Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

BioRem Inc. Revenue
Year Revenue Growth
2003 8.627.663
2004 2.421 -356267.74%
2005 10.712.854 99.98%
2006 12.008.313 10.79%
2007 9.469.955 -26.8%
2008 14.400.071 34.24%
2009 18.878.218 23.72%
2010 17.359.556 -8.75%
2011 12.045.195 -44.12%
2012 15.418.320 21.88%
2013 19.596.418 21.32%
2014 10.683.142 -83.43%
2015 16.880.173 36.71%
2016 15.896.146 -6.19%
2017 22.558.270 29.53%
2018 24.332.827 7.29%
2019 20.649.111 -17.84%
2020 24.375.343 15.29%
2021 24.477.997 0.42%
2022 28.862.972 15.19%
2023 22.037.232 -30.97%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

BioRem Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2003 132.658
2004 0 0%
2005 213.975 100%
2006 204.649 -4.56%
2007 921.343 77.79%
2008 1.032.714 10.78%
2009 1.191.540 13.33%
2010 1.758.772 32.25%
2011 1.071.652 -64.12%
2012 770.556 -39.08%
2013 586.561 -31.37%
2014 547.995 -7.04%
2015 444.357 -23.32%
2016 387.278 -14.74%
2017 393.974 1.7%
2018 271.523 -45.1%
2019 46.527 -483.58%
2020 30.510 -52.5%
2021 14.223 -114.51%
2022 97.123 85.36%
2023 19.380 -401.15%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

BioRem Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2003 0
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 1.699.873 100%
2009 1.158.520 -46.73%
2010 1.308.415 11.46%
2011 2.847.635 54.05%
2012 2.002.684 -42.19%
2013 2.196.472 8.82%
2014 1.691.773 -29.83%
2015 1.798.044 5.91%
2016 1.369.725 -31.27%
2017 2.141.004 36.02%
2018 2.857.176 25.07%
2019 4.101.434 30.34%
2020 2.804.969 -46.22%
2021 1.815.749 -54.48%
2022 3.202.565 43.3%
2023 1.032.180 -210.27%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

BioRem Inc. EBITDA
Year EBITDA Growth
2003 1.311.727
2004 -42.721 3170.45%
2005 1.037.497 104.12%
2006 -319.610 424.61%
2007 -1.395.707 77.1%
2008 188.079 842.09%
2009 366.728 48.71%
2010 -1.294.083 128.34%
2011 -2.310.644 43.99%
2012 -219.558 -952.41%
2013 1.645.779 113.34%
2014 -1.200.065 237.14%
2015 2.243.892 153.48%
2016 723.297 -210.23%
2017 1.695.116 57.33%
2018 774.305 -118.92%
2019 -1.093.393 170.82%
2020 2.915.624 137.5%
2021 2.677.489 -8.89%
2022 3.229.351 17.09%
2023 3.194.700 -1.08%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

BioRem Inc. Gross Profit
Year Gross Profit Growth
2003 3.759.478
2004 2.421 -155186.16%
2005 4.743.341 99.95%
2006 4.131.730 -14.8%
2007 3.344.403 -23.54%
2008 5.768.677 42.02%
2009 7.587.915 23.98%
2010 5.083.964 -49.25%
2011 2.869.289 -77.19%
2012 3.726.371 23%
2013 5.866.446 36.48%
2014 2.230.642 -162.99%
2015 5.995.413 62.79%
2016 4.107.395 -45.97%
2017 6.270.412 34.5%
2018 6.377.924 1.69%
2019 4.864.006 -31.12%
2020 7.016.699 30.68%
2021 6.236.413 -12.51%
2022 8.761.640 28.82%
2023 6.177.160 -41.84%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

BioRem Inc. Net Profit
Year Net Profit Growth
2003 1.925.715
2004 -25.221 7735.36%
2005 343.886 107.33%
2006 -769.674 144.68%
2007 -3.001.422 74.36%
2008 -432.236 -594.39%
2009 -502.838 14.04%
2010 -3.137.781 83.97%
2011 -3.369.416 6.87%
2012 -829.992 -305.96%
2013 717.625 215.66%
2014 -1.722.210 141.67%
2015 1.688.851 201.98%
2016 547.275 -208.59%
2017 1.530.116 64.23%
2018 4.665.763 67.21%
2019 -1.302.424 458.24%
2020 2.088.844 162.35%
2021 1.297.337 -61.01%
2022 1.613.057 19.57%
2023 2.012.372 19.84%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

BioRem Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2003 6
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

BioRem Inc. Free Cashflow
Year Free Cashflow Growth
2003 -321.184
2004 -23.398 -1272.7%
2005 -1.692.420 98.62%
2006 817.692 306.98%
2007 -2.187.841 137.37%
2008 -2.740.897 20.18%
2009 1.831.527 249.65%
2010 -2.199.471 183.27%
2011 593.022 470.89%
2012 -536.219 210.59%
2013 707.776 175.76%
2014 -475.395 248.88%
2015 2.142.923 122.18%
2016 -789.738 371.35%
2017 1.158.913 168.14%
2018 -233.244 596.87%
2019 2.392.405 109.75%
2020 2.993.010 20.07%
2021 3.705.823 19.23%
2022 1.241.625 -198.47%
2023 2.323.507 46.56%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

BioRem Inc. Operating Cashflow
Year Operating Cashflow Growth
2003 -285.975
2004 -23.398 -1122.22%
2005 -1.374.743 98.3%
2006 1.151.467 219.39%
2007 -2.069.790 155.63%
2008 -2.657.774 22.12%
2009 2.123.311 225.17%
2010 -1.857.163 214.33%
2011 905.259 305.15%
2012 -530.207 270.74%
2013 733.706 172.26%
2014 -445.593 264.66%
2015 2.149.387 120.73%
2016 -777.778 376.35%
2017 1.173.251 166.29%
2018 -2.526 46546.99%
2019 2.527.635 100.1%
2020 3.335.410 24.22%
2021 3.781.802 11.8%
2022 1.444.914 -161.73%
2023 2.564.441 43.66%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

BioRem Inc. Capital Expenditure
Year Capital Expenditure Growth
2003 35.209
2004 0 0%
2005 317.677 100%
2006 333.775 4.82%
2007 118.051 -182.74%
2008 83.123 -42.02%
2009 291.784 71.51%
2010 342.308 14.76%
2011 312.237 -9.63%
2012 6.012 -5093.56%
2013 25.930 76.81%
2014 29.802 12.99%
2015 6.464 -361.05%
2016 11.960 45.95%
2017 14.338 16.59%
2018 230.718 93.79%
2019 135.230 -70.61%
2020 342.400 60.51%
2021 75.979 -350.65%
2022 203.289 62.63%
2023 240.934 15.62%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

BioRem Inc. Equity
Year Equity Growth
2003 -968.762
2004 384.553 351.92%
2005 8.634.248 95.55%
2006 11.330.774 23.8%
2007 8.518.503 -33.01%
2008 8.789.452 3.08%
2009 8.547.816 -2.83%
2010 5.591.957 -52.86%
2011 629.110 -788.87%
2012 54.627 -1051.65%
2013 884.717 93.83%
2014 -258.087 442.8%
2015 1.933.405 113.35%
2016 2.426.948 20.34%
2017 7.299.311 66.75%
2018 12.895.065 43.39%
2019 11.723.767 -9.99%
2020 13.524.621 13.32%
2021 1.964.309 -588.52%
2022 4.520.553 56.55%
2023 4.492.176 -0.63%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

BioRem Inc. Assets
Year Assets Growth
2003 3.547.213
2004 395.613 -796.64%
2005 11.969.393 96.69%
2006 14.601.646 18.03%
2007 11.521.853 -26.73%
2008 16.928.209 31.94%
2009 15.149.442 -11.74%
2010 15.807.795 4.16%
2011 10.367.760 -52.47%
2012 9.780.423 -6.01%
2013 8.910.322 -9.77%
2014 7.689.130 -15.88%
2015 9.294.665 17.27%
2016 11.343.375 18.06%
2017 15.661.783 27.57%
2018 21.047.928 25.59%
2019 17.628.648 -19.4%
2020 21.952.883 19.7%
2021 19.166.054 -14.54%
2022 20.730.060 7.54%
2023 17.623.548 -17.63%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

BioRem Inc. Liabilities
Year Liabilities Growth
2003 4.515.975
2004 11.060 -40731.6%
2005 3.335.145 99.67%
2006 3.270.872 -1.97%
2007 3.003.350 -8.91%
2008 8.138.757 63.1%
2009 6.601.626 -23.28%
2010 10.215.838 35.38%
2011 9.738.650 -4.9%
2012 9.725.796 -0.13%
2013 8.025.605 -21.18%
2014 7.947.217 -0.99%
2015 7.361.260 -7.96%
2016 8.916.427 17.44%
2017 8.362.472 -6.62%
2018 8.152.863 -2.57%
2019 5.904.881 -38.07%
2020 8.428.262 29.94%
2021 17.201.745 51%
2022 16.209.507 -6.12%
2023 13.131.372 -23.44%

BioRem Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.52
Net Income per Share
0.04
Price to Earning Ratio
24.15x
Price To Sales Ratio
0.62x
POCF Ratio
4.87
PFCF Ratio
6.09
Price to Book Ratio
3.42
EV to Sales
0.67
EV Over EBITDA
9.08
EV to Operating CashFlow
5.04
EV to FreeCashFlow
6.56
Earnings Yield
0.04
FreeCashFlow Yield
0.16
Market Cap
0,01 Bil.
Enterprise Value
0,02 Bil.
Graham Number
0.51
Graham NetNet
-0.23

Income Statement Metrics

Net Income per Share
0.04
Income Quality
4.93
ROE
0.15
Return On Assets
0.04
Return On Capital Employed
0.18
Net Income per EBT
0.6
EBT Per Ebit
0.82
Ebit per Revenue
0.05
Effective Tax Rate
0.4

Margins

Sales, General, & Administrative to Revenue
0.11
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.27
Operating Profit Margin
0.05
Pretax Profit Margin
0.04
Net Profit Margin
0.03

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.2
Free CashFlow per Share
0.15
Capex to Operating CashFlow
-0.23
Capex to Revenue
-0.03
Capex to Depreciation
-2.4
Return on Invested Capital
0.09
Return on Tangible Assets
0.04
Days Sales Outstanding
133.71
Days Payables Outstanding
70.94
Days of Inventory on Hand
27.39
Receivables Turnover
2.73
Payables Turnover
5.15
Inventory Turnover
13.33
Capex per Share
-0.05

Balance Sheet

Cash per Share
0,15
Book Value per Share
0,29
Tangible Book Value per Share
0.29
Shareholders Equity per Share
0.29
Interest Debt per Share
0.24
Debt to Equity
0.79
Debt to Assets
0.2
Net Debt to EBITDA
0.65
Current Ratio
1.37
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0.79
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,01 Bil.
Average Payables
0,00 Bil.
Average Inventory
1190781.5
Debt to Market Cap
0.24

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

BioRem Inc. Dividends
Year Dividends Growth

BioRem Inc. Profile

About BioRem Inc.

BioRem Inc., a clean technology engineering company, designs, manufactures, distributes, and sells air pollution control systems that are used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). It offers biofilters for the removal of odors, H2S, VOCs, and HAPs; and biotrickling filters for applications of high levels of H2S or other water-soluble VOCs. The company also provides multi-stage systems to remove odors from various municipal/urban wastewater treatment processes; biogas desulfurization systems; dry scrubber adsorption systems; and cannabis odor control systems. In addition, it offers biological processes and testing services; media sampling and analysis; system review and inspections; and media replacements and spare parts. The company operates in Canada, the United States, China, and internationally. BioRem Inc. was founded in 1990 and is headquartered in Puslinch, Canada.

CEO
Mr. Derek S. Webb MBA, P.Eng.
Employee
57
Address
7496 Wellington Road 34
Puslinch, N0B 2J0

BioRem Inc. Executives & BODs

BioRem Inc. Executives & BODs
# Name Age
1 Mr. Derek S. Webb MBA, P.Eng.
Chief Executive Officer, President & Director
70
2 Mr. Douglas Newman
Chief Financial Officer & Secretary
70
3 Mr. Dan Costello
Director of Operations
70
4 Mr. Mark Smit
Director of Technical Services
70

BioRem Inc. Competitors